Picton Mahoney Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Picton Mahoney Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$1K	–	1140
2025 Q1	$1K	Buy	+50	New	+$2.08K	﹤0.01%	866
2024 Q3	–	Sell	-147	Closed	-$6K	–	938
2024 Q2	$6K	Buy	+147	New	+$6.28K	﹤0.01%	516
2015 Q1	–	Sell	-300	Closed	-$13K	–	349
2014 Q4	$13K	Buy	+300	New	+$13.7K	﹤0.01%	327

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Picton Mahoney Asset Management's RARE Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 50 shares — an estimated $1K sold.

Picton Mahoney Asset Management first reported a position in RARE in Q4 2014 and held it in 3 quarters. The position peaked at $13K in Q4 2014. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

Picton Mahoney Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Picton Mahoney Asset Management sold 50 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $1K.
Picton Mahoney Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and held it in 3 quarters.
Picton Mahoney Asset Management's Ultragenyx Pharmaceutical position peaked at $13K in Q4 2014.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.